ESR1 and neoplasm: Further an expression level after chemotherapy correlates to poor clinical response and a decreased level shows complete or partial clinical response [27]; also stromal CD10 expression significantly correlated with increasing tumor grade, mitotic rate, ER negativity, Her2neu positivity, and worse prognosis which suggests its role as a routine prechemotherapy marker in breast carcinoma [35].